Search this site powered by FreeFind




New Hope to Prevent Breast Cancer: What Every Woman Needs to Know


In March, 2005, a major nutritional breakthrough in the fight against breast cancer was announced by U.S. scientists. This new information is absolutely critical for every woman looking for a natural way to reduce breast cancer risk.

Researchers at Cornell University found that extracts from ordinary apples "effectively inhibited mammary cancer growth" in laboratory animals. The study concluded that "consumption of apples may be an effective strategy for cancer prevention."

The study, "Apples Prevent Mammary Tumors in Rats," was published in the Journal of Agricultural and Food Chemistry.

Phytochemicals from apples- known as polyphenols- have previously shown effectiveness against colon, lung, liver and stomach cancer, among others. But this is the first published study showing that apple polyphenols may be even more effective against breast cancer tumors.

Beyond Breast Cancer Prevention?

In the recent study, treatment with apple extracts prevented new tumor formation by up to 44% in animals given the highest amount.

But the most startling finding- and by far the most significant- is this: after 6 months of treatment, the number of existing tumors was reduced by 61%.

This remarkable finding indicates that adequate doses of apple polyphenols may go beyond prevention, and actually reduce existing mammary tumors.

What Can This Mean for You?

The researchers at Cornell believe that apple polyphenols may prevent breast cancer in humans. If this were the only study available, it might be too early to recommend increased doses of apple phytochemicals.

However, there are multiple studies in different types of cancer, showing that apple polyphenols are anti-proliferative, anti-mutagenic, and highly antioxidant. Consistent results have been obtained in studies on skin cancer, lung cancer, and six other types of human cancer cells.

Now, a new study from Cornell shows that apple polyphenols are also anti-metastatic- they seem to prevent cancers from spreading. This is a crucial finding for those at risk for breast cancer, as well as survivors of the disease.

Can I Just Eat More Apples?

In nearly all the available studies, the highest benefit from apple polyphenols comes with the highest intake. The Cornell scientists said the highest benefit was seen in rats eating the "human equivalent" of six apples a day.

There is no question that phytochemicals in apples are good for you. And one way to get more of them is to substantially increase the number of apples in your diet. But there's a problem...

Aside from the difficulty and expense of eating that many apples (42 apples a week), there is another important health issue- pesticides. Apples are one of the "dirtiest" foods in the U.S. when it comes to pesticides.

A Perfect Solution?

If you or someone you love is at risk for breast cancer, you need to know the answers to these three questions:

1. How many different pesticides are lurking in your apples?

2. Does washing the fruit take care of the problem? (This one may shock you.)

3. How can you get these apple phytochemicals with zero risk of pesticides?

Get the answers by clicking the link at the end of this article now...

David L. Kern is a researcher and publisher of New Health & Longevity, a newsletter devoted to the latest advances in medical nutritional science. Get the full story on this new health discovery now at http://www.applepoly.com/preventbreastcancer


MORE RESOURCES:
Breastfeeding for at least six months might lower the risk of developing so-called "triple negative" breast cancer, an aggressive form of the disease that is more common in black and younger women, according to a study published on Monday in the journal Cancer, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 8/24).

A new promising enzyme target for a specific type of breast cancer, Brk, has been identified in research published on August 21, 2008 in the Proceedings of the National Academy of Sciences (PNAS.) In a specific subset of breast cancer patients, the tumor cells produce high levels of the protein ErbB2 (also called HER2) which pushes the cells to proliferate without limit, a characteristic common of all cancers.

The American Medical Student Association (AMSA), the nation's oldest and largest, independent association for physicians-in-training, announces the commencement of AMSA Academy, a training ground for physician leaders. Established by students, for students, AMSA Academy takes medical students through the core competencies of leadership and project implementation, while building on key principles of important topics in medicine. There are currently 22 programs offered.

Happiness and optimism may play a role against breast cancer while adverse life events can increase the risk of developing the disease, according to a study by Professor Ronit Peled, at Ben-Gurion University of the Negev in Israel. An article on the study titled "Breast Cancer, Psychological Distress and Life Events among Young Women," was just published in the British journal BMC Cancer (8:245, August 2008).

Feelings of happiness and optimism play a positive role against breast cancer. Research published in the open access journal BMC Cancer suggests that while staying positive has a protective role, adverse life events such as the loss of a parent or close relative, divorce or the loss of a spouse can increase a woman's risk of developing the disease.

New research may explain why breast cancer tends to be more aggressive in women with denser breast tissue. Breast cancer cells grown in dense, rigid surroundings step up their invasive activities, Vanderbilt-Ingram Cancer Center investigators report in the Sept. 9 issue of Current Biology. The findings suggest a cellular mechanism for the correlation between human breast tissue density and tumor aggressiveness.

Two independent research groups have found that simultaneous inhibition of two signaling pathways resulted in substantially enhanced antitumor effects in mouse models of prostate and breast cancer. In an accompany commentary, Steven Grant, at Virginia Commonwealth University Health Science Center, Richmond, discusses the clinical importance of these studies and highlights some of the questions that still need to be answered.

A new study published on bmj.com argues that for older women, health related quality of life can be improved by hormone replacement therapy (HRT). The authors recommend that HRT guidelines should be revised with this most current evidence taken into consideration. Earlier studies have shown that HRT has the potential for general improvements in quality of life measures - how patients feel or function.

Duke University chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected. The researchers also deduced that this molecule -- called largazole -- acts on cells through the same chemical mechanism as other anti-cancer compounds on the market or in clinical trials.

Seeking to improve on nature, scientists used a spice-based compound as a starting point and developed synthetic molecules that, in lab settings, are able to kill cancer cells and stop the cells from spreading. The researchers are combining organic chemistry, computer-aided design and molecular biology techniques in developing and testing pharmaceutical compounds that can fight breast and prostate cancer cells.

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that the first patient has been treated in a global Phase 3 clinical trial of IMC-1121B, its anti-vascular endothelial growth factor receptor-2 (VEGFR-2) IgG1 monoclonal antibody, in women with metastatic breast cancer.

Advocates, including those for breast cancer patients, are concerned about their relationship with pharmaceutical company Genentech following Roche's bid for the company, the

A decade-long Nebraska study that showed disparities in breast and cervical cancer screenings could have spurred changes that raised the percentage of women screened in the state. "Disparities in screening between racial and ethnic groups, even in a homogeneous state such as Nebraska, are a problem and by digging into some of the differences we were able to have an impact on breast and cervical cancer screening," said lead study author Shingairai Feresu, Ph.D.

Women who survive breast cancer for at least five years after treatment have an 89% chance that they will not have a recurrence of the cancer after 10 years and an 81% chance after 15 years, according to a study published online Tuesday in the Journal of the National Cancer Institute,

Research by scientists at the University of Sheffield suggests that the combination of zoledronic acid (a drug used to prevent bone loss) and chemotherapy agent doxorubicin could stop the growth of breast cancer tumours. Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "Breakthrough welcomes any research which investigates new uses for existing treatments to help benefit people with breast cancer.

An article published in The Lancet Oncology reports that postmenopausal women with breast cancer who are on endocrine treatment are likely to experience arthralgia and arthritis (joint symptoms) if they previously have used hormone replacement therapy (HRT), received a hormone-receptor positive tumor diagnosis, undergone chemotherapy, received treatment with anastrozole versus tamoxifen, or been obese.

Scientists in the UK and Finland have discovered that a new combination of the chemotherapy drug doxorubicin and the bone-protecting drug zoledronic acid, both of which are considerably cheaper than herceptin, stopped breast cancer tumors growing in mice. Experts suggest that since both drugs are already in use, and if the combination proves effective and safe in human clinical trials, it should not take as long for it to be available as a new treatment for patients.

Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.

Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.

Famous names from the fashion, television, radio and music industries have come together to back Fashion Targets Breast Cancer® (FTBC) UK in an advertising campaign which subtly plays on the topic of celebrity charity endorsement. Natalie Imbruglia, Anna Friel, Alan Carr, Edith Bowman and Twiggy have been shot by acclaimed photographer Rankin wearing their FTBC T-shirts with pride for the campaign from leading charity Breakthrough Breast Cancer which aims to raise £1m.

US researchers estimated that the risk of relapse for breast cancer patients who were cancer-free for five years after systemic therapy (chemotherapy, hormone therapy, or both, as well as surgery) was not negligible although it was probably lower than many people realized.

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.

American Airlines, the world's largest airline, and Susan G. Komen for the Cure®, the world's largest breast cancer organization, announced an expanded partnership with the unveiling of two specially co-branded aircraft, an American Airlines Boeing 757 and an American Eagle Embraer 145, each incorporating the renowned vivid pink-ribbon motif.

Geron Corporation (Nasdaq: GERN) announced the enrollment of the first patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in locally recurrent or metastatic breast cancer. The primary objective of the Phase I/II, dose escalation study is to determine the safety, maximum tolerated dose (MTD) and objective response rate of GRN163L when administered intravenously in combination with a paclitaxel/bevacizumab regimen in this patient population.

A new discovery may lead to more effective screening and treatment for patients with a difficult to recognize syndrome characterized by tumor-like growths and a high risk of developing specific cancers. The research, published by Cell Press in the August 7 issue of the American Journal of Human Genetics, is the first in over thirteen years to identify an alternate susceptibility gene for Cowden syndrome (CS) and related disorders.

home | site map| privacy policy
© 2008, Celerity Consultants, Mumbai, India, All Rights Reserved